Navigation Links
Synvista Therapeutics Announces Progress in Phase 2 Clinical Trial Program for Alagebrium
Date:1/12/2009

MONTVALE, N.J., Jan. 12 /PRNewswire-FirstCall/ -- Synvista Therapeutics, Inc. (NYSE Alternext US: SYI) has completed enrollment of its BENEFICIAL study, a Phase 2 double-blind, placebo-controlled, randomized trial of the Company's compound alagebrium. The study is designed to measure the effect of alagebrium on exercise tolerance in patients with chronic systolic heart failure. In addition, the Company anticipates completing enrollment of its BREAK (Beginning a Randomized Evaluation of the A.G.E. [Advanced Glycation End Product] Breaker Alagebrium in Diastolic Heart Failure) study in the First Quarter of 2009. BREAK, a randomized, double-blind, placebo controlled study, evaluates whether alagebrium (200mg twice daily) can improve exercise tolerance, as measured by the 6-minute walk test, in patients diagnosed with diastolic heart failure.

"We are extremely pleased with the progress thus far in our clinical program for alagebrium," said Noah Berkowitz, M.D., Ph.D., President and Chief Executive Officer of Synvista Therapeutics, developer of alagebrium. "Based on our dialogue with the FDA, we believe that exercise tolerance is an approvable regulatory endpoint, in patients with systolic or diastolic heart failure. Accordingly, we look forward to the timely completion of these studies which could provide proof of efficacy and a partial basis for drug approval."

About Alagebrium

Alagebrium is Synvista's clinical candidate for interfering with A.G.E.-related sclerosis and fibrosis of the heart, kidney and other tissues leading to heart failure, diabetic nephropathy and other disorders. It is a proprietary A.G.E. crosslink breaker that is designed to function unlike any previously developed pharmaceutical agents to reverse the disease states associated with age or diabetes-related stiffening of vessels, tissues and organs. Alagebrium has completed a series of
'/>"/>

SOURCE Synvista Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Synvista Therapeutics to Present at the BIO InvestorForum 2007
2. Synvista Therapeutics to be Featured on Wallst.net
3. Synvista Therapeutics to Develop Topical Formulation of ALT-2074 for the Treatment of Psoriasis
4. Synvista Therapeutics to Present at the 10th Annual BIO CEO & Investor Conference
5. Synvista Therapeutics Highlights Newly Published Data Demonstrating the Value of Haptoglobin Genotype Testing In People with Diabetes
6. Synvista Therapeutics Increases Commercial Focus by Appointing David C. Tantillo Senior Director of Marketing and Sales
7. Synvista Therapeutics to Present at Acumen BioFin Rodman & Renshaw 5th Annual Global Healthcare Conference
8. Synvista Therapeutics Announces Initiation of the BREAK Study of Alagebrium for Diastolic Heart Failure
9. Vista Partners Initiates Coverage on Synvista Therapeutics, Inc. (AMEX: SYI)
10. Synvista Therapeutics Posts Letter to Stockholders on Web Site
11. Synvista Therapeutics Announces Availability of Haptoglobin Genotyping Technology at The Annual Scientific Sessions of the American Heart Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... 2014 Nerium International, the go-to, ... the spotlight again. Nerium will showcase its signature ... Body Contouring Cream to Hollywood’s elite at the ... the 66th Primetime Emmy® Awards. , Developed from ... clinical trials show that NeriumAD night cream dramatically ...
(Date:8/21/2014)... research group at the Institute for Molecular Medicine ... Stockholm, has developed a novel "man and machine" ... innovative diagnostic aid was described in PLOS ... method is based on computer vision algorithms similar ... with visualization of only the diagnostically most relevant ...
(Date:8/21/2014)... , Aug. 21, 2014 Telomere ... of their Nutraceutical "TELO-20 for Dogs" with ... Telomere-lengthening supplement in the world for dogs. Telomeres ... every chromosome in the body. A wealth of ... experts in Telomere Science and Aging, including Nobel ...
(Date:8/21/2014)... , Aug. 21, 2014  China Cord Blood Corporation ... its plan to release financial results for the first ... 2014, after market close in the US.  ... 8:00 a.m. ET on Friday, August 29, 2014 to ... of the Company,s recent developments, followed by a question ...
Breaking Biology Technology:Nerium International Joins Television’s Biggest Stars at Backstage Creations Giving Suite at the 66th Primetime Emmy Awards 2Nerium International Joins Television’s Biggest Stars at Backstage Creations Giving Suite at the 66th Primetime Emmy Awards 3A novel 'man and machine' decision support system makes malaria diagnostics more effective 2Telomere Biosciences Announces: TELO-20 for Dogs, the World's First Telomere-Lengthening Supplement for Dogs, to Promote Healthy Aging and Longevity 2Telomere Biosciences Announces: TELO-20 for Dogs, the World's First Telomere-Lengthening Supplement for Dogs, to Promote Healthy Aging and Longevity 3China Cord Blood Corporation to Report First Quarter of Fiscal 2015 Financial Results 2
... Genaera,Corporation (Nasdaq: GENR ) today announced the ... Directors, bringing the membership total to,seven. Dr. Wotton is ... term through the Company,s 2009 Annual Meeting., "We ... Board of Directors.,He has a proven record of success ...
... Commercialize ... Novel Technology from UC Davis, BOSTON, June 30 ... university business ventures, has,established RF Biocidics, Inc., to develop and ... The newly formed RF Biocidics, Inc. is developing a ...
... PITTSBURGH, June 30 Cellumen, Inc., the Cellular,Systems ... research,collaboration with the National Center for Toxicology Research ... Administration (FDA). Under the,agreement, Cellumen will use its ... samples of known liver toxicity,compounds including both failed ...
Cached Biology Technology:Genaera Corporation Elects Paul K. Wotton to Board of Directors 2Genaera Corporation Elects Paul K. Wotton to Board of Directors 3Genaera Corporation Elects Paul K. Wotton to Board of Directors 4Allied Minds Launches Novel Disinfectant/Disinfestant Technology Start-up With UC Davis 2Cellumen to Collaborate With the NCTR of the FDA to Apply Cellular Systems Biology (CSB(TM)) to Predictive Toxicology 2
(Date:8/22/2014)... French . NAIROBI ... African soils looming as a major threat to food security ... over the last five years, 1.7 million African farmers in ... million hectares and helped them double or even triple crop ... Revolution in Africa (AGRA) focuses on intensive efforts initiated five ...
(Date:8/22/2014)... . , Thanks ... in a way so as to align themselves symmetrically, ... University researchers are planning on looking into how PCFs ... being published today in the scientific journal Nature ... Everyone knows that at least from having boiled ...
(Date:8/22/2014)... Stanford, CAEveryone,s heard of the birds and the ... flowers that are being fertilized. The fertilization process ... extensive communication between the male and female reproductive ... Stanford, Regensburg, Heidelberg, and Munich, and including Carnegie,s ... discoveries in the chemical signaling process that guides ...
Breaking Biology News(10 mins):Effort to confront Africa's soil health crisis helps millions of farmers triple yields 2Effort to confront Africa's soil health crisis helps millions of farmers triple yields 3Effort to confront Africa's soil health crisis helps millions of farmers triple yields 4Proteins: New class of materials discovered 2Calcium and reproduction go together 2
... Investigators at Georgia State University,s Neuroscience Institute and ... identify the most likely reason analgesic drug treatment ... This discovery is a major step toward finding ... pain. "Opioid-based narcotics (such as morphine) are ...
... season, think twice about spending money on a commercial ... methodkeeping your tree in a container of fresh wateris ... and healthy. Researchers have determined that some flame retardants ... several cases the chemical retardants sped up the drying ...
... published in the December 23rd issue of Current Biology ... select shade-grown coffee over beans that were grown in the ... of birds and bats, but they also help to maintain ... farms allow birds and bats to move and disperse seeds ...
Cached Biology News:Study first to pinpoint why analgesic drugs may be less potent in females than in males 2Flame retardants prove ineffective on fresh-cut Christmas trees 2Another reason to drink a nice cup of shade-grown joe 2
Phospho-Cyclin D1 (Thr286) Antibody...
Rabbit polyclonal to SpUlp2 ( Abpromise for all tested applications). Antigen: Synthetic peptide: SNNERQSLSSGSND, corresponding to amino acids 622-635 of Schizosaccharomyces pombe SpUlp2...
Rabbit polyclonal to Factor IX ( Abpromise for all tested applications). entrezGeneID: 2158 SwissProtID: P00740...
Mouse monoclonal [CLB-SW16 (formerly 708)] to CD42d (rating: ****) ( Abpromise for all tested applications). entrezGeneID: 2814 SwissProtID: P40197...
Biology Products: